Skip navigation
sponsored by 

Panel backs second cervical cancer vaccine

Committee finds Cervarix a safe alternative to Gardasil

FirstPerson
Standing up to cancer
TODAY viewers who have battled breast cancer share their stories of survival and lessons learned.
Quiz
What do you know about breast cancer?
How old was Betty Ford when she had a mastectomy? How many women are affected by the disease each year? Take our iCue video quiz and find out.

TODAY

  Join the Army of Women
A message from Dr. Susan Love, MD

The time has come for all women to stand up and say that we are not going to take it anymore!  Breast cancer does not have to go on to another generation; we can be the ones who stop it once and for all!  Join the Love/Avon Army of Women for you mother, sister, friend and daughter so that no one ever has to hear the words “you have breast cancer” again!

  Video: Dr. Love announces her Army of Women initiative on TODAY

Slide show
Image: Maura Tierney
  Famous breast cancer survivors
Actresses, singers and a politician’s wife who’ve all been diagnosed with the disease reveal their strength to keep fighting.

more photos

Breast cancer videos
TODAY
Look and feel your best after cancer
Oct. 27:  Three experts share advice for breast cancer survivors on coping with the appearance-related side effects of breast cancer treatment.

updated 1:56 p.m. ET Oct. 21, 2009

ATLANTA - A federal vaccine advisory panel has voted to recommend a second kind of vaccine against cervical cancer for girls and young women.

The government last week licensed the vaccine, Cervarix from GlaxoSmithKline, for marketing in the United States. Merck & Co. has had the vaccine Gardasil on the market since 2006.

The committee voted Wednesday to recommend Cervarix as an alternative. It did not state a preference of one vaccine over the other. But officials noted that while both protect against forms of the virus that cause cervical, vaginal and vulvar cancers, the older Merck vaccine also protects against forms that cause genital warts. Both shots are a three-dose series. The Merck series costs about $390 and Glaxo's costs about $385.

Story continues below ↓
advertisement | your ad here

The CDC still has to adopt the new recommendation for it to become official.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sponsored links

Resource guide